Agency Turns Down Merck's Arcoxia

Drug Industry Daily
KEYWORDS FDA
A A
The FDA has issued a not approvable letter for Merck's Vioxx successor Arcoxia, telling the company it will require additional data to support the risk-benefit profile of the drug.

To View This Article:

Login

Subscribe To Drug Industry Daily